Skip to main content
Erschienen in: European Archives of Oto-Rhino-Laryngology 1/2013

01.01.2013 | Head and Neck

Management and outcome of salivary duct carcinoma in major salivary glands

verfasst von: Elina Salovaara, Olli Hakala, Leif Bäck, Petri Koivunen, Kauko Saarilahti, Fabricio Passador-Santos, Ilmo Leivo, Antti A. Mäkitie

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with poor prognosis. Its histomorphology is distinctly reminiscent of the ductal carcinoma of the breast. We reviewed the treatment and outcome of SDCs at a single tertiary care centre. Twenty-five cases of SDC of major salivary gland origin, diagnosed and treated at the Department of Otolaryngology, Head and Neck Surgery, Helsinki University Central Hospital, Helsinki, Finland, during a 14-year period from 1997 to 2011, were reviewed retrospectively. Survival outcome was analyzed for 18 patients with a minimum follow-up of 24 months. There were 16 male (64 %) and 9 female (36 %) patients with a median age of 61 years (range 36–82 years). The majority of the cases occurred in the parotid gland (n = 21, 84 %) followed by the submandibular gland (n = 4, 16 %). The primary treatment consisted of surgical resection in all cases and 17 (68 %) patients also underwent neck dissection. Most of the patients (n = 18, 72 %) were treated with postoperative radiotherapy. Seven patients (28 %) had a disease recurrence within a median follow-up time of 15 months (range 3–27 months). In the group (n = 18) with a minimum follow-up time of 24 months, the 2- and 5-year overall and disease-specific survival rates were 66, 41 % and 75, 55 %, respectively. These results confirm the aggressive nature of SDCs in major salivary glands. Diagnostics and management of these tumours need to be centralized in experienced surgical Head and Neck Oncology Centres, and new treatment strategies should be investigated.
Literatur
2.
Zurück zum Zitat Luukkaa H, Klemi P, Leivo I, Koivunen P, Laranne J, Mäkitie A, Virtaniemi J, Hinkka S, Grénman R (2005) Salivary gland cancer in Finland 1991–96: an evaluation of 237 cases. Acta Otolaryngol 125:207–214PubMedCrossRef Luukkaa H, Klemi P, Leivo I, Koivunen P, Laranne J, Mäkitie A, Virtaniemi J, Hinkka S, Grénman R (2005) Salivary gland cancer in Finland 1991–96: an evaluation of 237 cases. Acta Otolaryngol 125:207–214PubMedCrossRef
3.
Zurück zum Zitat Kleinsasser O, Klein HJ, Hubner G (1968) Salivary duct carcinoma: a group of salivary gland tumors analogous to mammary duct carcinoma (German). Arch Klin Exp Ohren Nasen Kehlkopfheilkd 192:100–105PubMedCrossRef Kleinsasser O, Klein HJ, Hubner G (1968) Salivary duct carcinoma: a group of salivary gland tumors analogous to mammary duct carcinoma (German). Arch Klin Exp Ohren Nasen Kehlkopfheilkd 192:100–105PubMedCrossRef
4.
Zurück zum Zitat Etges A, Pinto DS Jr, Kowalski LP, Soares FA, Araujo VC (2003) Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. J Clin Pathol 56:914–918PubMedCrossRef Etges A, Pinto DS Jr, Kowalski LP, Soares FA, Araujo VC (2003) Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. J Clin Pathol 56:914–918PubMedCrossRef
5.
Zurück zum Zitat Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, Dietz-Band J, James W, Slamon DJ, Batsakis JG et al (1994) Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 54:5675–5682PubMed Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, Dietz-Band J, James W, Slamon DJ, Batsakis JG et al (1994) Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 54:5675–5682PubMed
6.
Zurück zum Zitat Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Löning T (2005) Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 103:2526–2533PubMedCrossRef Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Löning T (2005) Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 103:2526–2533PubMedCrossRef
7.
Zurück zum Zitat Skálová A, Stárek KucerováV, Szépe P, Plank L (2001) Salivary duct carcinoma—a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. Pathol Res Pract 197:621–626PubMedCrossRef Skálová A, Stárek KucerováV, Szépe P, Plank L (2001) Salivary duct carcinoma—a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. Pathol Res Pract 197:621–626PubMedCrossRef
8.
Zurück zum Zitat Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK (2010) Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res 16:2266–2274PubMedCrossRef Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK (2010) Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res 16:2266–2274PubMedCrossRef
9.
Zurück zum Zitat Prat A, Parera M, Reyes V, Peralta S, Cedrés S, Andreu J, Huguet P, del Campo JM (2008) Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck 30:680–683PubMedCrossRef Prat A, Parera M, Reyes V, Peralta S, Cedrés S, Andreu J, Huguet P, del Campo JM (2008) Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck 30:680–683PubMedCrossRef
10.
Zurück zum Zitat Nabili V, Tan JW, Bhuta S, Sercarz JA, Head CS (2007) Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck 29:907–912PubMedCrossRef Nabili V, Tan JW, Bhuta S, Sercarz JA, Head CS (2007) Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck 29:907–912PubMedCrossRef
11.
Zurück zum Zitat Nashed M, Casasola RJ (2009) Biological therapy of salivary duct carcinoma. J Laryngol Otol 123:250–252PubMedCrossRef Nashed M, Casasola RJ (2009) Biological therapy of salivary duct carcinoma. J Laryngol Otol 123:250–252PubMedCrossRef
12.
Zurück zum Zitat Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD (1996) Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer 77:223–230PubMedCrossRef Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD (1996) Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer 77:223–230PubMedCrossRef
13.
Zurück zum Zitat Hosal AS, Fan C, Barnes L, Myers EN (2003) Salivary duct carcinoma. Otolaryngol Head Neck Surg 129:720–725PubMedCrossRef Hosal AS, Fan C, Barnes L, Myers EN (2003) Salivary duct carcinoma. Otolaryngol Head Neck Surg 129:720–725PubMedCrossRef
14.
Zurück zum Zitat Guzzo M, Di Palma S, Grandi C, Molinari R (1997) Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck 19:126–133PubMedCrossRef Guzzo M, Di Palma S, Grandi C, Molinari R (1997) Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck 19:126–133PubMedCrossRef
15.
Zurück zum Zitat Moriki T, Ueta S, Takahashi T, Mitani M, Ichien M (2001) Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer 93:344–350PubMedCrossRef Moriki T, Ueta S, Takahashi T, Mitani M, Ichien M (2001) Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer 93:344–350PubMedCrossRef
16.
Zurück zum Zitat Delgado R, Vuitch F, Albores-Saavedra J (1993) Salivary duct carcinoma. Cancer 72:1503–1512PubMedCrossRef Delgado R, Vuitch F, Albores-Saavedra J (1993) Salivary duct carcinoma. Cancer 72:1503–1512PubMedCrossRef
17.
Zurück zum Zitat Kapadia SB, Barnes L (1998) Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod Pathol 11:1033–1038PubMed Kapadia SB, Barnes L (1998) Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod Pathol 11:1033–1038PubMed
18.
Zurück zum Zitat Fan CY, Wang J, Barnes EL (2000) Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistological analysis of 13 cases and review of the literature. Am J Surg Pathol 24:579–586PubMedCrossRef Fan CY, Wang J, Barnes EL (2000) Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistological analysis of 13 cases and review of the literature. Am J Surg Pathol 24:579–586PubMedCrossRef
19.
Zurück zum Zitat Williams MD, Roberts DE, Blumenschein GR, Temam S, Kies MS, Rosenthal DI, Weber RS, El-Naggar AK (2007) Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol 31:1645–1652PubMedCrossRef Williams MD, Roberts DE, Blumenschein GR, Temam S, Kies MS, Rosenthal DI, Weber RS, El-Naggar AK (2007) Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol 31:1645–1652PubMedCrossRef
20.
Zurück zum Zitat Jaspers HC, Verbist BM, Schoffelen R, Mattijssen V, Slootweg PJ, van der Graaf WT, van Herpen CM (2011) Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol 29:473–476CrossRef Jaspers HC, Verbist BM, Schoffelen R, Mattijssen V, Slootweg PJ, van der Graaf WT, van Herpen CM (2011) Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol 29:473–476CrossRef
21.
Zurück zum Zitat Locati LD, Quattrone P, Bossi P, Marchianò AV, Cantù G, Licitra L (2003) A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann Oncol 14:1327–1328PubMedCrossRef Locati LD, Quattrone P, Bossi P, Marchianò AV, Cantù G, Licitra L (2003) A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann Oncol 14:1327–1328PubMedCrossRef
22.
Zurück zum Zitat Felix A, El-Naggar AK, Press MF, Ordonez NG, Fonseca I, Tucker SL, Luna MA, Batsakis JG (1996) Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol 27:561–566PubMedCrossRef Felix A, El-Naggar AK, Press MF, Ordonez NG, Fonseca I, Tucker SL, Luna MA, Batsakis JG (1996) Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol 27:561–566PubMedCrossRef
23.
Zurück zum Zitat Roh JL, Cho KJ, Kwon GY, Choi SH, Nam SY, Kim SY (2008) Prognostic values of pathologic findings and hypoxia markers in 21 patients with salivary duct carcinoma. J Surg Oncol 97:596–600PubMedCrossRef Roh JL, Cho KJ, Kwon GY, Choi SH, Nam SY, Kim SY (2008) Prognostic values of pathologic findings and hypoxia markers in 21 patients with salivary duct carcinoma. J Surg Oncol 97:596–600PubMedCrossRef
24.
Zurück zum Zitat Feinstein TM, Lai SY, Lenzner D, Gooding W, Ferris RL, Grandis JR, Myers EN, Johnson JT, Heron DE, Argiris A (2011) Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy. Head Neck 33:318–323PubMed Feinstein TM, Lai SY, Lenzner D, Gooding W, Ferris RL, Grandis JR, Myers EN, Johnson JT, Heron DE, Argiris A (2011) Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy. Head Neck 33:318–323PubMed
25.
Zurück zum Zitat Adelstein DJ, Rodriguez CP (2011) What is new in the management of salivary gland cancers? Curr Opin Oncol 23:249–253PubMedCrossRef Adelstein DJ, Rodriguez CP (2011) What is new in the management of salivary gland cancers? Curr Opin Oncol 23:249–253PubMedCrossRef
26.
Zurück zum Zitat Cornolti G, Ungari M, Morassi ML, Facchetti F, Rossi E, Lombardi D, Nicolai P (2007) Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland. Arch Otolaryngol Head Neck Surg 133:1031–1036PubMedCrossRef Cornolti G, Ungari M, Morassi ML, Facchetti F, Rossi E, Lombardi D, Nicolai P (2007) Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland. Arch Otolaryngol Head Neck Surg 133:1031–1036PubMedCrossRef
27.
Zurück zum Zitat Milano A, Longo F, Basile M, Iaffaioli RV, Caponigro F (2007) Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy. Oral Oncol 43:729–734PubMedCrossRef Milano A, Longo F, Basile M, Iaffaioli RV, Caponigro F (2007) Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy. Oral Oncol 43:729–734PubMedCrossRef
Metadaten
Titel
Management and outcome of salivary duct carcinoma in major salivary glands
verfasst von
Elina Salovaara
Olli Hakala
Leif Bäck
Petri Koivunen
Kauko Saarilahti
Fabricio Passador-Santos
Ilmo Leivo
Antti A. Mäkitie
Publikationsdatum
01.01.2013
Verlag
Springer-Verlag
Erschienen in
European Archives of Oto-Rhino-Laryngology / Ausgabe 1/2013
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-012-1997-4

Weitere Artikel der Ausgabe 1/2013

European Archives of Oto-Rhino-Laryngology 1/2013 Zur Ausgabe

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.